Related Experiment Video
Updated: Jun 23, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
Patent foramen ovale and migraine: association, causation, and implications of clinical trials
Stewart J Tepper1, Catalina Cleves, Frederick R Taylor
1Center for Headache and Pain, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. teppers@ccf.org
Abstract:
Patent foramen ovale (PFO) appears to be associated with migraine with aura (MA), probably through cardiac shunting. PFOs may also be comorbid with cryptogenic strokes. Although multiple open-label, retrospective, and case-controlled studies have noted sometimes dramatic reductions of MA after PFO closure, the only prospective sham-controlled study of PFO closure for MA, MIST, was negative for all primary and secondary measures of migraine improvement. MIST did demonstrate an association between MA and severe PFO shunts prospectively. Difficulty with recruitment closed the MIST II and ESCAPE trials; the PREMIUM and PRIMA randomized controlled trials are ongoing at the time of this writing.
Insights
Patent foramen ovale (PFO) closure may not improve migraine with aura (MA) symptoms, despite observational studies suggesting a link. The MIST trial found no benefit, though it confirmed an association between severe PFO shunts and MA.
Area of Science:
- Cardiology
- Neurology
- Medical Devices
Background:
- Patent foramen ovale (PFO) is frequently observed in patients with cryptogenic stroke and migraine with aura (MA).
- Previous studies suggested PFO closure could significantly reduce MA frequency, but evidence from rigorous trials is limited.
- The MIST trial was the first prospective, sham-controlled study investigating PFO closure for MA.
Purpose of the Study:
- To evaluate the efficacy of PFO closure in reducing migraine with aura symptoms.
- To investigate the association between PFO characteristics and MA.
- To assess the safety and effectiveness of PFO closure in a randomized, sham-controlled setting.
Main Methods:
- The study involved a prospective, randomized, sham-controlled design.
- Participants with MA and PFO underwent either PFO closure or a sham procedure.
- Primary and secondary endpoints focused on migraine improvement and reduction in MA frequency.
Main Results:
- The MIST trial did not meet its primary or secondary endpoints for migraine improvement following PFO closure.
- However, the study prospectively confirmed a significant association between MA and severe PFO shunts.
- Recruitment challenges led to the early termination of subsequent trials like MIST II and ESCAPE.
Conclusions:
- Current evidence from the MIST trial does not support routine PFO closure for the treatment of migraine with aura.
- A strong association persists between severe PFO shunts and MA, warranting further investigation.
- Ongoing trials like PREMIUM and PRIMA aim to provide further insights into this complex relationship.
Related Concept Videos
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Increased Intracranial Pressure ll: Pathophysiology

